|
**Overview**: **Respiratory Comprehensive Profile****Introduction**: The Respiratory Comprehensive Profile is a diagnostic tool designed to detect respiratory pathogens using sputum or bronchoalveolar lavage (BAL) samples. Associated with conditions like pneumonia and bronchitis, these disorders present with cough, fever, and severe complications if untreated, particularly in individuals with suspected respiratory infections. Per the 2023 Bacteriology, Virology, Mycology, and Molecular Pathology guidelines, the test employs bacteriology, virology, mycology, and molecular pathology with PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for respiratory infection screening in clinical settings. This diagnostic falls under respiratory infection screening and targets individuals with suspected respiratory pathogens, addressing the challenge of accurate pathogen detection to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its sample-based approach ensures reliable detection.**Other Names**: Resp Comp Pfl.**FDA Status**: FDA approved, CLIA certified for bacteriology, virology, mycology, and molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by infectious disease labs, this test advanced respiratory pathogen screening.**Purpose**: The test screens for 30 parameters including Streptococcus pneumoniae to guide respiratory infection assessment, assess pathogen presence and resistance, and inform treatment and prevention strategies.**Test Parameters**: 1. Streptococcus pneumoniae, 2. Haemophilus influenzae, 3. Moraxella catarrhalis, 4. Staphylococcus aureus, 5. Klebsiella pneumoniae, 6. Pseudomonas aeruginosa, 7. Acinetobacter baumannii, 8. Escherichia coli, 9. Legionella pneumophila, 10. Mycoplasma pneumoniae, 11. Chlamydia pneumoniae, 12. Influenza A, 13. Influenza B, 14. Parainfluenza Virus, 15. Respiratory Syncytial Virus, 16. Rhinovirus, 17. Adenovirus, 18. Human Metapneumovirus, 19. Enterovirus, 20. Coronavirus, 21. Candida albicans, 22. Aspergillus fumigatus, 23. Pneumocystis jirovecii, 24. Bordetella pertussis, 25. Bordetella parapertussis, 26. Antibiotic Resistance (mecA), 27. Antibiotic Resistance (blaKPC), 28. Antibiotic Resistance (blaNDM), 29. Antibiotic Resistance (blaVIM), 30. Antibiotic Resistance (blaOXA).**Pretest Condition**: No fasting required; patients should report cough, fever, or recent respiratory symptoms.**Specimen**: 2 mL sputum or BAL in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 1 month at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cough, fever, prior respiratory reactions, or family history of respiratory infections, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated respiratory infections including lung damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antibiotic use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible respiratory infections, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in pulmonology or infectious disease should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Chest X-ray or culture for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Bacteriology, Virology, Mycology, and Molecular Pathology Guidelines 2023, Journal of Respiratory Medicine 2024, Chemistry 2025. |
